Viewing Study NCT01980524



Ignite Creation Date: 2024-05-06 @ 2:11 AM
Last Modification Date: 2024-10-26 @ 11:14 AM
Study NCT ID: NCT01980524
Status: COMPLETED
Last Update Posted: 2017-04-04
First Post: 2013-10-26

Brief Title: The Impact of Free Fatty Acid FFA- Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
Sponsor: Medical University of Vienna
Organization: Medical University of Vienna

Study Overview

Official Title: HYPOglycemia Linked to Cardiac sTEatoSIS - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes HYPOTESIS
Status: COMPLETED
Status Verified Date: 2017-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HYPOTESIS
Brief Summary: There is evidence that inhibition of FFA-release by acipimox is associated with a significant decrease in myocardial lipid content MYCL as well as the ejection fraction as a marker of systolic left ventricular function in healthy subjects indicating that the heart is dependent on a constant supply of free fatty acids in order to guarantee normal cardiac function and it further indicates that the heart is not able to cover its energy demand by switching to glucose oxidation

Since that phenomenon better known as metabolic inflexibility has been mainly described in patients with diabetes we aim to investigate the impact of FFA-inhibition on MYCL and cardiac function in patients with overt type 2 diabetes
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2013-002656-32 EUDRACT_NUMBER None None